Adipogen/Ursodeoxycholic acid/AG-CN2-0411-G005/5 g
商品编号：
AG-CN2-0411-G005
品牌：
Adipogen Inc
市场价：
¥2400.00
美元价：
1440.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Product Details | |
|---|---|
| Synonyms | UDCA; USAN; BRN 3219888; NSC 657950; NSC 683769 |
| Product Type | Chemical |
| Properties | |
| Formula | C24H40O4 |
| MW | 392.6 |
| Merck Index | 14: 9889 |
| CAS | 128-13-2 |
| RTECS | FZ2000000 |
| Source/Host Chemicals | Synthetic. |
| Purity Chemicals | ≥95% (NMR) |
| Appearance | White to off-white powder. |
| Solubility | Soluble in DMSO, ethanol or dimethylformamide. Sparingly soluble in water. |
| Identity | Determined by 1H-NMR. |
| InChi Key | RUDATBOHQWOJDD-UZVSRGJWSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | +4°C |
| Handling Advice |
Protect from light. Protect from moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
- Endogenous hydrophilic bile acid.
- Antioxidant. Cytoprotective against oxidative stress and cell death.
- Hepatoprotective at cellular and molecular level, including stabilization of membranes. Protects hepatocytes against bile acid-induced apoptosis.
- Antiapoptotic and antinecrotic. Targets the mitochondrial function and integrity, reduction of endoplasmatic stress and interactions with survival signals in cAMP, Akt, NF-κB, MAPK and PI3K signaling pathways.
- Modulator and finetuner of the p53-Mdm-2 complex.
- Chemopreventive against colorectal cancer by countering the tumor-promoting effects of secondary bile acids. Shows also effects on epidermal growth factor receptor (EGFR) signaling and COX-2 expression.
- Immunomodulator and anti-inflammatory compound. Modifies TLR4 and TLR9 signaling pathways and downregulates the production of proinflammatory tumor necrosis factor-α (TNF-α).
- Pregnane X receptor agonist.
- Neuroprotective. Inhibits neuronal apoptosis.
- Glucocorticoid Receptor (GR) agonist.
- Anticholestatic agent. Used to reduce cholesterol absorption and for cholesterol gallstone dissolution.
- Used to treat primary biliary cirrhosis (PBC).
- Interferes with the progression of non-alcoholic fatty liver disease (NAFLD)/NASH.
- Reduces CXCR3 expression [11].
- TIMP-1 inducer [12].
- ADAM17 inhibitor [12].
Product References
- Antioxidant properties of ursodeoxycholic acid: D. Lapenna, et al.; Biochem. Pharmacol. 64, 1661 (2002) (Review)
- Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited: G. Paumgartner, et al.; Hepatology 36, 525 (2002) (Review)
- Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatmen. T.C. Schreuder, et al.; World J. Gastroenterol. 14, 2474 (2008) (Review)
- p53 and the regulation of hepatocyte apoptosis: implications for disease pathogenesis: J.D. Amaral, et al.; Trends Mol. Med. 15, 531 (2009) (Review)
- Bile acids: regulation of apoptosis by ursodeoxycholic acid: J.D. Amaral, et al.; J. Lipid. Res. 50, 1721 (2009) (Review)
- Bile acids as regulators of hepatic lipid and glucose metabolism: M. Trauner, et al.; Dig. Dis. 28, 220 (2010) (Review)
- Targeting the p53 pathway of apoptosis: J.D. Amaral, et al.; Curr. Pharm. Des. 16, 2493 (2010) (Review)
- Ursodeoxycholic acid and chemoprevention of colorectal cancer: L. Serfaty, et al.; Gastroenterol. Clin. Biol. 34, 516 (2010) (Review)
- Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action: R. Poupon; Clin. Res. Hepatol. Gastroenterol. 36, S3 (2012) (Review)
- Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications: M.G. Roma, et al.; Clin. Sci. (Lond). 121, 523 (2011) (Review)
- CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid: P. Manousou, et al.; Clin. Exp. Immunol. 172, 9 (2013)
- Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity: H. Buryova, et al.; BMC Gastroenterol. 13, 155 (2013)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
